[68Ga]Ga-Pentixafor PET/CT 用于初诊多发性骨髓瘤 Durie-Salmon PLUS 分期与危险分层
该前瞻性研究纳入 69 例初诊多发性骨髓瘤(NDMM)患者,比较 [68Ga]Ga-Pentixafor 与 [18F]FDG PET/CT 的 Durie-Salmon PLUS 分期性能和高危预测能力。结果显示 [68Ga]Ga-Pentixafor 阳性检出率、SUVmax、SUVmean、TLR 和 TBS 均高于 [18F]FDG,且能更好识别晚期患者;其 SUVmeanCXCR4 和 TBSCXCR4 是预测高危 NDMM 的独立指标。
要点
- [68Ga]Ga-Pentixafor 阳性检出率 82.6%(57/69)高于 [18F]FDG 的 53.6%(37/69),P < 0.001。
- [68Ga]Ga-Pentixafor 识别晚期患者 53 例,多于 [18F]FDG 的 35 例,P < 0.001。
- SUVmeanCXCR4(OR = 1.752,95%CI 1.085–2.828,P = 0.022)和 TBSCXCR4(OR = 1.041,95%CI 1.011–1.072,P = 0.008)为高危独立指标。
核心结论
- 在 NDMM 中,[68Ga]Ga-Pentixafor 的诊断准确性、Durie-Salmon PLUS 分期及高危预测能力均优于 [18F]FDG PET/CT。
- [68Ga]Ga-Pentixafor 衍生的 SUVmeanCXCR4 和 TBSCXCR4 可准确识别高危 NDMM。
研究设计与样本
- 最终分析 69 例参与者,其中男性 40 例,中位年龄 64 岁(IQR 57–71.5 岁)。
主要发现
- [68Ga]Ga-Pentixafor 阳性检出率 82.6%(57/69)高于 [18F]FDG 的 53.6%(37/69),P < 0.001。
- [68Ga]Ga-Pentixafor 的 SUVmax 为 13.5,高于 [18F]FDG 的 5.3,P < 0.001;SUVmean 为 3.5 对比 2.9,P = 0.029。
- [68Ga]Ga-Pentixafor 的 TLR 为 8.1,高于 [18F]FDG 的 2.0,P < 0.001;TBS 为 45 对比 4,P < 0.001。
- [68Ga]Ga-Pentixafor 衍生的 TBSCXCR4、TBMVCXCR4 和 TBMUCXCR4 分别与骨髓浆细胞百分比、β2-微球蛋白和总附加评分正相关。
- Durie-Salmon PLUS 分期中,[68Ga]Ga-Pentixafor 识别晚期患者 53 例,多于 [18F]FDG 的 35 例,P < 0.001。
关键数值与推荐
- 按 Mayo mSMART 4.0 分层系统,多因素 logistic 回归显示 SUVmeanCXCR4(OR = 1.752,95%CI 1.085–2.828,P = 0.022)和 TBSCXCR4(OR = 1.041,95%CI 1.011–1.072,P = 0.008)为预测高危 NDMM 的独立指标。
临床怎么用
- 对初诊多发性骨髓瘤患者,[68Ga]Ga-Pentixafor PET/CT 可较 [18F]FDG 检出更多病灶并支持更准确的 Durie-Salmon PLUS 分期。
- 可利用 [68Ga]Ga-Pentixafor 衍生的 SUVmeanCXCR4 和 TBSCXCR4 辅助识别高危 NDMM 患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to assess and compare the Durie-Salmon PLUS staging performance and high-risk prediction capabilities between [68Ga]Ga-Pentixafor and [18F]FDG PET/CT in newly diagnosed multiple myeloma (NDMM). METHODS: Eligible participants with NDMM who underwent [68Ga]Ga-Pentixafor and [18F]FDG PET/CT between October 2021 and March 2025 were prospectively enrolled in this study (NCT05255926). The diagnostic and staging performance of [68Ga]Ga-Pentixafor and [18F]FDG were assessed and compared. The parameters including standardized uptake value (SUV), tumor-to-liver ratio (TLR), total bone marrow uptake (TBMU), total bone marrow uptake volume (TBMV), and total burden score (TBS) were calculated. Independent predictors for high-risk NDMM were identified using single-factor and multivariate logistic regression. RESULTS: Sixty-nine participants (40 men) with a median age of 64 years (interquartile range [IQR], 57–71.5 years) were finally analysed. [68Ga]Ga-Pentixafor PET/CT exhibited a higher positive detection rate (82.6% [57/69] vs. 53.6% [37/69], P < 0.001), maximum SUV (SUVmax; 13.5 vs. 5.3 P < 0.001), mean SUV (SUVmean; 3.5 vs. 2.9, P = 0.029), TLR (8.1 vs. 2.0, P < 0.001), and TBS (45 vs. 4, P < 0.001) than [18F]FDG. [68Ga]Ga-Pentixafor-derived TBSCXCR4, TBMVCXCR4, and TBMUCXCR4 positively correlated with bone marrow plasma cell percentage, β2-microglobulin, and total additive score, respectively. For Durie-Salmon PLUS staging, [68Ga]Ga-Pentixafor better identified advanced participants than did [18F]FDG PET/CT (53 vs. 35; P < 0.001). According to the Mayo mSMART 4.0 stratification system, multivariate logistic regression analysis demonstrated that SUVmeanCXCR4 (odds ratio [OR] = 1.752, 95% confidence interval [CI] = 1.085– 2.828, P = 0.022) and TBSCXCR4 (OR = 1.041, 95% CI = 1.011–1.072, P = 0.008) were independent indicators for predicting high-risk NDMM. CONCLUSION: In NDMM, [68Ga]Ga-Pentixafor demonstrated better diagnostic accuracy, Durie-Salmon PLUS staging, and high-risk prediction capabilities than did [18F]FDG PET/CT. [68Ga]Ga-Pentixafor-derived SUVmeanCXCR4 and TBSCXCR4 could accurately identify high-risk NDMM. Trial registration number: NCT05255926.
引用
- Chen J, Tang S, Liu L, et al. [68Ga]Ga-Pentixafor PET/CT for Durie-Salmon PLUS staging and risk stratification in newly diagnosed multiple myeloma. Eur J Nucl Med Mol Imaging. 2026. PMID: 41760826. doi:10.1007/s00259-026-07813-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。